Dutch Acute HCV in HIV Study (DAHHS-2): Grazoprevir/Elbasvir for Acute HCV (DAHHS-2)
Grazoprevir (MK-5172)+ Elbasvir (MK-8742) for the Treatment of Acute Hepatitis C Genotype 1/4. The Dutch Acute HCV in HIV Study (DAHHS-2)
Sponsor: Erasmus Medical Center
This PHASE3 trial investigates Acute Hepatitis C and Hepatitis C and is currently completed. Erasmus Medical Center leads this study, which shows 10 recorded versions since 2016 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE3
▶ Show 5 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE3
-
Aug 2019 — Jan 2021 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jun 2018 — Aug 2019 [monthly]
Active Not Recruiting PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Mar 2018 [monthly]
Recruiting PHASE3
First recorded
Feb 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Erasmus Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .